Boehringer Nabs Extra Indication for Giotrif in EU

The European Commission has given the green light to Boehringer Ingelheim’s Giotrif for the treatment of advanced squamous cell lung cancer.

Giotrif — which already is approved for the treatment of EGFR mutation-positive non-small cell lung cancer in the EU — met its primary endpoint in a Phase 3 trial of reducing the risk of cancer progression by 19 percent. It also reduced the risk of death by 19 percent.

The drug is approved in more than 60 countries — including the U.S. — for the first-line treatment of EGFR mutation-positive NSCLC.